IN8bio (INAB)
Develops gamma-delta T-cell therapies and engagers for cancer and autoimmune disease.
Something off on this page? Send us feedback.
Develops gamma-delta T-cell therapies and engagers for leukemia, glioblastoma, oncology, and B-cell-driven autoimmune disease. The development-stage company has no approved products or product revenue and depends on clinical progress, regulatory approval, manufacturing partners, licensed intellectual property, and financing.
Develops expanded and genetically engineered gamma-delta T-cell therapies and T-cell engagers through the DeltEx platform. Clinical programs include donor-derived INB-100 after transplant for high-risk leukemia and INB-200, an autologous cell therapy delivered with standard care for newly diagnosed glioblastoma. INB-619 is a preclinical CD19-directed engager for oncology and B-cell-driven autoimmune applications.
Operates from New York with primary research operations in Birmingham and conducts U.S. clinical work through academic centers. Its work centers on gamma-delta T-cell expansion, engineering, and manufacturing, while the company relies on contract manufacturers, licensed university intellectual property, regulatory clearance, and external financing. It has no approved or marketed products and reports a single operating segment.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Oct 13, 2025 | Mizuho Securities | Target | Target: — | Target: $4 |
| Feb 11, 2025 | Jones Trading | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $18.0M · Total debt $2.2M · Total assets $21.7M · Shareholders' equity $18.4M
- Revenue
- $0
- Operating income
- −$4.8M
- Net income
- −$4.8M
No dividends on record.
| Institutions | 38.44% | 3.79M shares | |
|---|---|---|---|
| 21 holders · as of Jun 30, 2026 | |||
| Insiders | 12.87% | 1.27M shares | |
| 6 holders · as of Mar 2, 2026 | |||
| Other | 48.69% | 4.80M shares | |
| remainder | |||
9.86M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Lytton Laurence W.Insider | 9.98% | 984,031 | filed Mar 2, 2026 |
Alyeska Investment Group, L.P.Institution | 9.58% | 944,319 | as of Jun 30, 2026 |
Franklin Resources IncInstitution | 9.28% | 914,531 | as of Jun 30, 2026 |
683 Capital Management, LLCInstitution | 7.35% | 724,637 | as of Jun 30, 2026 |
Stonepine Capital Management, LLCInstitution | 7.05% | 695,287 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Adicet Bio
Allogeneic gamma-delta CAR-T programs overlap in B-cell depletion.
- CytoMed Therapeutics
Donor-derived gamma-delta cell programs overlap in AML and solid tumors.
- Amgen
Approved CD19 T-cell engagement benchmarks the preclinical engager.
- Senti Biosciences
Off-the-shelf CAR-NK therapy contests the AML cell-therapy setting.
- Genmab (ADR)
Subcutaneous CD20 T-cell engagement overlaps in B-cell malignancies.
- Century Therapeutics
Allogeneic CD19 CAR-iT development overlaps with the engager program.
- Immatics
Allogeneic gamma-delta and T-cell-engager platforms overlap in solid tumors.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| IN8bio | $1.14 | +7.78% | $10.2M | — | — | — | — |
| Adicet Bio | $9.28 | +3.92% | $83.5M | — | — | — | — |
| CytoMed Therapeutics | $0.9099 | −6.20% | $11.5M | — | — | — | +30.5% |
| Amgen | $409.34 | +4.11% | $212.19B | 24.4 | 17.4 | 5.6 | +9.7% |
| Senti Biosciences | $0.3250 | +4.84% | $9.7M | — | — | 175.5 | — |
| Genmab (ADR) | $35.21 | +1.48% | $21.30B | 27.3 | 26.9 | 5.2 | +24.9% |
| Century Therapeutics | $1.91 | +3.24% | $160.2M | — | — | — | — |
| Immatics | $8.87 | +1.66% | $1.17B | — | — | 24.5 | +113.0% |
| Median | 25.9 | 22.2 | 15.0 | +27.7% |